Prakt. lékáren. 2021; 17(1): 7-13 | DOI: 10.36290/lek.2021.001

Possibilities and principles of vaccination against COVID-19

Michal Křupka1, Petr Kosztyu1, Mojmír Račanský1, 2*, Jan Schovánek3*, Kristýna Sloupenská1, Jan Strojil4*, Milan Raška1
1 Ústav imunologie Lékařské fakulty Univerzity Palackého v Olomouci
2 Oddělení alergologie a klinické imunologie, Fakultní nemocnice Olomouc
3 III. interní klinika - nefrologická, revmatologická, endokrinologická, Fakultní nemocnice Olomouc a Lékařské fakulty Univerzity Palackého v Olomouci
4 Ústav farmakologie Lékařské fakulty Univerzity Palackého v Olomouci
* Lékaři pracující na covidových pracovištích Fakultní nemocnice Olomouc

For the majority of people, the year 2020 will be inseparably linked to the COVID-19 pandemic which was caused by SARS-CoV-2. By January 1, 2021, nearly 84 million COVID-19 cases and more than 1.8 million COVID-19 associated deaths were confirmed worldwide. Implemented intensive anti-epidemic measures contributed to temporal reduction of the infection spread but they substantially influenced the social life, education system and economy on a global scale. After the anti-epidemic measures were relaxed, virus spread rate increased in the population immediately. Initially expected elicitation of herd immunity is under doubtable. Great expectations are therefore pinned on the introduction of preventive vaccination.The first vaccines are now available, however, the distrust of a part of the general public and, unfortunately, also a part of the health-care professionals seems to be a possible obstacle for its successful use. The aim of this article is to present the topical overview of the issue of SARS-CoV-2 vaccination including basic principles of new types of gene vaccines.

Keywords: COVID-19, SARS‑CoV-2, vakccine, mRNA, adenovirus.

Published: April 15, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Křupka M, Kosztyu P, Račanský M, Schovánek J, Sloupenská K, Strojil J, Raška M. Possibilities and principles of vaccination against COVID-19. Praktické lékárenství. 2021;17(1):7-13. doi: 10.36290/lek.2021.001.

Download citation

References

  1. Beneš J a kol. Infekční lékařství. Galén, Praha 2009, 651 s.
  2. Collier L, Kellam P, Oxford J. Human Virology. Oxford University Press Inc. New York 2011, 365 s.
  3. Cui J, Li F, Shi, Z‑L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol 2019; 17(3):181-192. Go to original source... Go to PubMed...
  4. Chan‑Yeung M, Xu RH. SARS: epidemiology. Respirology 2003; 8 Suppl 1: S9-14. Go to original source... Go to PubMed...
  5. Al‑Omari A, Rabaan AA, Salih S, Al‑Tawfiq JA, Memish ZA. MERS coronavirus outbreak: Implications for emerging viral infections. Diagn Microbiol Infect, DiS. 2019; 93(3): 265-285. Go to original source... Go to PubMed...
  6. World Health Organization. Clinical management of COVID-19: interim guidance, 27 May 2020 [online] https://apps.who.int/iris/handle/10665/332196 [cit. 2021-01-22]. Go to original source...
  7. COVID-19 and VTE/Anticoagulation: Frequently Asked Questions. American Society of Hematology [online] https://www.hematology.org/covid-19/covid-19-and‑vte‑anticoagulation [cit. 2020-12-24].
  8. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. N Engl J Med 2020; NEJMoa2021436.
  9. Siemieniuk R, Rochwerg B, Agoritsas T, et al. A living WHO guideline on drugs for covid-19. BMJ 2020; 370: m3379. Go to PubMed...
  10. Lund LC, Kristensen KB, Reilev M, et al. Adverse outcomes and mortality in users of non‑steroidal anti‑inflammatory drugs who tested positive for SARS‑CoV-2: A Danish nationwide cohort study. PLoS Med 2020; 17: e1003308. Go to original source... Go to PubMed...
  11. Position Statement of the ESC Council on Hypertension on ACE‑Inhibitors and Angiotensin Receptor Blockers [online] https://www.escardio.org/Councils/Council‑on‑Hypertension-(CHT)/News/position‑statement‑of‑the‑esc‑council‑on‑hypertension‑on‑ace‑inhibitors‑and‑ang [cit. 2021-1-21].
  12. Simonovich VA, Burgos Pratx LD, Scibona P, et al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia. N Engl J Med 2020; NEJMoa2031304. Go to PubMed...
  13. US FDA. Coronavirus (COVID-19) Update: FDA Revokes Emergency Use Authorization for Chloroquine and Hydroxychloroquine. June 15, 2020 [online]. https://www.fda.gov/news‑events/press‑announcements/coronavirus‑covid-19-update‑fda‑revokes‑emergency‑use‑authorization‑chloroquine‑and [cit. 2021-1-21].
  14. RECOVERY Collaborative Group. Lopinavir‑ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open‑label, platform trial. Lancet 2020; 96(10259): 1345-1352. Go to original source...
  15. Heidary F, Gharebaghi R. Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen. J Antibiot (Tokyo) 2020; 73: 593. Go to original source... Go to PubMed...
  16. Smolej L. Posouzení publikace "Inosine Pranobex Significantly Decreased the Case‑Fatality Rate among PCR Positive Elderly with SARS‑CoV-2 at Three Nursing Homes in the Czech Republic". Beran J et al., Pathogens 2020. Český klub skeptiků Sisyfos [online] https://bit.ly/3iKPQ4g [cit. 2021-01-25].
  17. Post N, Eddy D, Huntley C, van Schalkwyk MCI, Shrotri M et al. Antibody response to SARS‑CoV-2 infection in humans: A systematic review. PLoS One 2020; 15(12): e0244126. Go to original source... Go to PubMed...
  18. Lau EHY, Tsang OTY, Hui DSC, Kwan MYW, Chan W‑H et al. Neutralizing antibody titres in SARS‑CoV-2 infections. Nat Comm 2021; 12: 63. Go to original source... Go to PubMed...
  19. Martinon F, Krishnan S, Lenzen G, Magné R, Gomard E, et al. Induction of virus‑specific cytotoxic T lymphocytes in vivo by liposome‑entrapped mRNA. Eur J Immunol. 1993; 23(7): 1719-1722. Go to original source... Go to PubMed...
  20. Ulmer, JB, Donnelly JJ, Parker SE, Rhodes GH, Felgner, PL et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993; 259 (5102): 1745-1749. Go to original source... Go to PubMed...
  21. Běláková J, Horynová M, Křupka M, Weigl E, Raška M. DNA vaccines: are they still just a powerful tool for future? Arch Immunol Ther Exp 2007; 55: 387-398. Go to original source... Go to PubMed...
  22. Karikó K, Muramatsu H, Welsh FA, Ludwig J, Kato H. Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther 2008; 16(11): 1833-1840. Go to original source... Go to PubMed...
  23. Akinc A, Maier AM, Manoharan M, Fitzgerald K, Jayaraman M et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid‑based drugs. Nature Nanotechnology 2019; 14: 1084-1087. Go to original source... Go to PubMed...
  24. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018; 17(4): 261-279. Go to original source... Go to PubMed...
  25. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383 (27): 2603-2615. Go to original source... Go to PubMed...
  26. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, et al. Efficacy and Safety of the mRNA-1273 SARS‑CoV-2 Vaccine. N Engl J Med 2020. NEJMoa2035389. Go to original source... Go to PubMed...
  27. Wold WSM, Toth K. Adenovirus Vectors for Gene Therapy, Vaccination and Cancer Gene Therapy. Curr Gene Ther. 2013; 13(6): 421-433. Go to original source... Go to PubMed...
  28. Garofalo M, Staniszewska M, Salmaso S, Caliceti P, Pancer KW, Wieczorek M, Kuryk L. Prospects of Replication‑Deficient Adenovirus Based Vaccine Development against SARS‑CoV-2. Vaccines (Basel) 2020; 8(2): 293. Go to original source... Go to PubMed...
  29. Dicks MDJ, Spencer AJ, Edwards NJ, Wadell G, Bojang K, Gilbert SC, et al. A Novel Chimpanzee Adenovirus Vector with Low Human Seroprevalence: Improved Systems for Vector Derivation and Comparative Immunogenicity. PLoS ONE 2012; 7(7): e40385. Go to original source... Go to PubMed...
  30. Morris SJ, Sebastian S, Spencer AJ, Gilbert SC. Simian adenoviruses as vaccine vectors. Future Virol. 2016; 11(9): 649-659. Go to original source... Go to PubMed...
  31. Folegatti PM, Bittaye M, Flaxman A, Lopez FR, Bellamy D et al. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral‑vectored vaccine: a dose‑escalation, open‑label, non‑randomised, uncontrolled, phase 1 trial. Lancet Infect, DiS. 2020; 20(7): 816-826. Go to original source... Go to PubMed...
  32. Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS‑CoV-2: an interim analysis of fourrandomised controlled trials in Brazil, South Africa, and the UK. Lancet 2020; 397(10269): 99-111. Go to original source... Go to PubMed...




Pharmacy for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.